Corporate Profile for Bradley Pharmaceuticals, dated July 4, 1997.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: July 4, 1997
Company Name: Bradley Pharmaceuticals Inc.
Address: 383 Route 46 West
Fairfield, NJ 07004
Main Telephone
Number: 973/882-1505
Internet Home
Page Address
(URL) www.bradpharm.com
Chief Executive
Officer: Daniel Glassman
Chief Financial
Officer: Larry Lenz
Investor Relations
Contact: Daniel Glassman
Business number: 973/882-1505
Industry: Brand Name Pharmaceutical Manufacturer
Market Makers: See Note (A)
Company description: Overview Bradley Pharmaceuticals Bradley Pharmaceuticals is a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey. The company was founded in 1985 by Daniel Glassman who is at the current time its CEO. The company markets to niche physician specialties in the U.S. Inc., manufactures and markets brandname prescription and over-the-counter pharmaceutical and health-related products throughout the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. as well as in twenty-five international markets. Its Doak Dermatologics subsidiary markets products in the dermatologic dermatological, dermatologic pertaining to dermatology; of or affecting the skin. field and will shortly enter a dermatological dermatological, dermatologic pertaining to dermatology; of or affecting the skin. product research and development phase of corporate growth. The Kenwood Laboratories division primarily markets respiratory therapy respiratory therapy Medical profession concerned with assisting the respiratory function of individuals who have severe lung disorders. Practices include suctioning to clear secretions from the airway, use of aerosol mists (sometimes medicated) or gases to ease breathing, products. Bradley Common Class A Shares (BPRX) are traded on the NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on National Market System. Mission: Bradley Pharmaceuticals' mission is two-fold: -- Develop Doak Dermatologics into a leading dermatological company -- Develop Kenwood Laboratories into a broad based respiratory therapy company Strategy To Achieve Mission Doak Dermatologics will develop through licensing, acquisition, and internal research and development. Kenwood Laboratories will develop through licensing and acquisition. Revenue growth will generate from innovative marketing, expanding distribution domestically, securing profitable contracts with institutional groups and continued strengthening of our international distributors. Key Position Statement Bradley Pharmaceuticals' primary goal is to acquire safe and effective niche-oriented brands that have a well-established sales base and a high profit potential, then, move these products forward by extending their life cycles through creative marketing, the introduction of line extensions and effective promotion. June 1997 Statistics: Nasdaq NM Symbol BPRX Common Stock 7,634,931(B) @ total outstanding Class B, Common Stock 431,552 52 week price range: $1 21/32 to 5/8 Recent Price $1 3/8 Fiscal Year Ends December 31 Market Makers: (A) DH Blair, Brooklyn Capital, Troster Singer, Wien Securities, Herzog Heine Geduld, Knight Securities, Frankel & Co., Ladenburg Thalmann Ladenburg Thalmann is a small New York City investment bank and broker founded in 1876. The firm became a member of the New York Stock Exchange in 1879 and was a major Wall Street player into the 1950s. , Mayer & Schweitzer, MH Meyerson, Nash Weiss, Paragon Capital, Spencer Trask Spencer Trask was an American financier, philanthropist, and venture capitalist. Beginning in the 1870s, Trask began investing and supporting entrepreneurs, including Thomas Edison's invention of the electric light bulb. (B) As of 6/20/97 Financial Highlights ($, except shares: 000s, except per share) Dec. 31 Dec. 31 Dec. 31 Dec. 31 Dec. 31 1996 1995 1994 1993 1992 Net Sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight 12,769 10,621 20,147 6,412 1,687 Net Income (loss) 1,599 (6,921) 3,769 906 (657) Earnings (loss) per share 0.22 (0.94) 0.27 0.16 (0.30) Weighted Avg. Shares 7,200 7,300 16,700 8,800 2,200 Total Assets 20,703 26,900 28,200 22,100 4,300 Total long-term debt Long-Term Debt Loans and financial obligations lasting over one year. Notes: For example debts obligations such as bonds and notes which have maturities greater than one year would be considered long-term debt. 500 4,500 5,700 7,800 600 Shareholders' equity Shareholders' Equity A firms' total assets minus its total liabilities. Equivalently, it is share capital plus retained earnings minus treasury shares. Shareholders' equity is the amount by which a company is financed through common and preferred shares. 11,800 8,900 14,300 9,700 2,500 Computation of net income per common share for the years ended 1993 and 1994 were computed using the modified treasury stock method. Computation of the net income (loss) per common share for the years ended 1992, 1995 and 1996 do not include the effect of stock equivalents because the inclusion of such stock equivalents would be antidilutive. CONTACT: Bradley Pharmaceuticals Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion